extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
b2c0573daa
commit
7bfdf26607
6 changed files with 64 additions and 1 deletions
|
|
@ -53,6 +53,12 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
|
|||
|
||||
At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Medicare-specific modeling shows net savings of $715M over 10 years when multi-indication benefits are included, with T2D savings ($892M) exceeding obesity costs ($205M). The distinction is critical: system-level inflation can coexist with payer-level savings when the entity bearing drug costs also captures downstream disease prevention savings. This suggests the 'inflationary through 2035' claim needs scope qualification between fee-for-service system economics and risk-bearing payer economics.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -54,6 +54,12 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
|
|||
|
||||
Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Quantified multi-organ savings in Medicare population: $14,431/subject from avoided T2D, $2,074/subject from avoided CKD, $1,512/subject from avoided CV events. Per 100,000 subjects: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided. The compounding effect is measurable and substantial enough to offset $47,353 average lifetime treatment costs.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -40,6 +40,12 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k
|
|||
|
||||
SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Medicare-specific modeling quantifies CKD savings at $2,074 per subject treated, which is smaller than T2D savings ($14,431/subject) but still material. The 10-year window may underestimate CKD value since dialysis costs accumulate over longer timeframes.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -47,6 +47,12 @@ PACE represents the 100% risk endpoint—full capitation for all medical, social
|
|||
|
||||
The BALANCE Model moves payment toward genuine risk by adjusting capitated rates for obesity and increasing government reinsurance for participating MA plans. This creates a direct financial incentive mechanism where plans profit from preventing obesity-related complications rather than just managing them. The model explicitly tests whether combining medication access with lifestyle supports under risk-bearing arrangements can shift the payment boundary.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
The Medicare semaglutide analysis demonstrates why full-risk arrangements change prevention economics: when the same entity pays for drugs AND captures downstream savings, comprehensive GLP-1 access becomes cost-saving ($715M over 10 years). This is the mechanism by which risk-bearing payment models enable prevention investments that fee-for-service cannot justify.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,24 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-bears-both-costs-and-downstream-savings.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"comprehensive-glp-1-access-saves-medicare-money-when-single-payer-bears-both-costs-and-downstream-savings.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"comprehensive-glp-1-access-saves-medicare-money-when-single-payer-bears-both-costs-and-downstream-savings.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-06-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -39,3 +43,14 @@ Key findings:
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
|
||||
EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare net savings projection: $715M over 10 years (range $412M-$1.04B)
|
||||
- 38,950 cardiovascular events avoided over 10 years
|
||||
- 6,180 deaths avoided (CV + CKD/MASH)
|
||||
- T2D-related savings: ~$892M
|
||||
- Obesity-related costs: ~$205M
|
||||
- MASH-related savings: ~$28M
|
||||
- Average per-subject lifetime treatment costs: $47,353
|
||||
- Per-subject savings breakdown: T2D $14,431, CKD $2,074, CV events $1,512
|
||||
|
|
|
|||
Loading…
Reference in a new issue